RecruitingNCT05855941

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)

Sponsor

Region Västerbotten

Enrollment

120 participants

Start Date

May 23, 2023

Study Type

OBSERVATIONAL

Conditions

Endometrial Cancer Epithelial Ovarian Cancer Cervix Cancer

Summary

The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: * Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will * Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether advanced medical imaging tests (such as MRI and PET scans) can improve the diagnosis and prediction of outcomes for women with gynecological cancers — specifically cervical cancer, endometrial (uterine) cancer, and ovarian cancer. **You may be eligible if...** - You are over 18 years old - You have been newly diagnosed with cervical, endometrial, or suspected ovarian cancer (not yet treated) - Your cancer stage is known - You have not had any other cancer in the last 10 years **You may NOT be eligible if...** - Your imaging shows signs of a different type of cancer - You have a device implanted in your body that is not compatible with MRI (like certain pacemakers) - Your suspected ovarian cancer turns out to be a different diagnosis after enrollment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFDG-PET/CT and FDG-PET/MRI

Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.

Locations(1)

Centre for Gynecology and Obstetrics, Umea University Hospital

Umeå, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05855941

Related Trials

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT0512348267 locations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT0548921196 locations

ASk Questions in GYnecologic Oncology (ASQ-GYO)

NCT063398271 location

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT0689033866 locations

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT0651561314 locations